AXIM
AXIM Biotechnologies, Inc.0.0170
+0.0010+6.25%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
5.66MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
8-K
Control shifts to Kettner
AXIM Biotechnologies underwent a change of control effective October 15, 2024, when Kettner Investments acquired all Series C Preferred Stock—entitling holders to appoint a board majority—in a debt-swap deal settling $515,000 owed by Juniper to MJNA and waiving MJNA's $1.09M notes plus $66,000 interest. Amid this, Catalina Valencia stepped in as President on October 9 due to John Huemoeller II's illness; he died October 12, prompting her Series C Director appointment October 14. New leadership now steers the biotech.
10-Q
Q2 FY2024 results
AXIM Biotechnologies posted Q2 revenue of $17K, up 76% y/y from $10K yet flat q/q as test shipments continued through partner Verséa; six-month sales doubled to $70K y/y (derived). Operating loss narrowed 18% y/y to $569K on 17% lower expenses, while net loss swung to $2.3M from $3.7M as derivative fair-value losses eased—net exceeded operating by >20% due to $1.4M change in derivative liability and $179K interest. Cash dwindled to $6K amid $514K YTD operating burn, offset by $366K financing; total liabilities hit $13.3M including $6.7M long-term convertibles (3-5% rates, maturities to 2034). Cash stays razor-thin. Derivative volatility looms large.
10-Q
Q1 FY2024 results
AXIM Biotechnologies posted Q1 revenue of $53K, up sharply from $7K y/y, from deferred license fees and test shipments to partner Verséa Ophthalmics. Operating loss narrowed to $404K from $711K y/y as SG&A fell 43%, yet net loss shrank to $292K from $2.8M thanks to a $334K gain on derivative liability fair-value change—net loss exceeded operating by less than 20%. Cash dipped to $97K q/q amid $1.1M operating burn, offset by $1.0M financing including S-1 stock sales; stockholders' deficit improved to $7.4M. Debt stands at $11.4M (mostly convertibles), with $3.5M eye-care intangibles amortizing over 9.1 years. Verséa just ordered 50 more readers. CLIA moderate complexity limits adoption.
10-K
FY2023 results
AXIM Biotechnologies posted FY2023 revenue of $39,518, up sharply from $8,875 in 2022, fueled by initial commercialization of FDA-cleared dry eye diagnostics via partner Verséa Ophthalmics, which fulfilled part of a 19,000-test order while placing for 50 more readers in early 2024. Yet operating expenses fell 41% to $2.8M and net loss widened to $8.1M from $6.2M, hit by $955K litigation settlement and ongoing debt costs amid $5.8M working capital deficit. Q4 saw manufacturing ramp-up and equipment acquisition via 7.3M shares. Cash burned $1.0M in operations. Debt overhang looms large.
8-K
Convertible notes settle debts
AXIM Biotechnologies issued $814,555 in convertible notes on March 15, 2024, to directors, officers, contractors, and Sapphire employees, settling past-due fees and salaries at 4.25% interest maturing March 1, 2034. Notes convert into 47.7M shares at $0.01-$0.02 after two years or stock hitting $0.20 for 30 days—yet non-transferable. Also issued 1.1M restricted shares for $11,000 owed. Dilution looms large.
ADPT
Adaptive Biotechnologies Corpor
15.93+0.24
AIMD
Ainos, Inc.
2.15+0.00
BJDX
Bluejay Diagnostics, Inc.
0.97-0.04
CDXS
Codexis, Inc.
1.68+0.05
EXOZ
eXoZymes Inc.
12.52-1.78
IMA
ImageneBio, Inc.
6.25+0.08
NRXS
Neuraxis, Inc.
2.70+0.05
OCUL
Ocular Therapeutix, Inc.
14.39+0.22
RTGN
RETINALGENIX TECHNOLOGIES INC
3.20+0.00
VRAX
Virax Biolabs Group Limited
0.40-0.01